Ondansetron-loaded chitosan microspheres for nasal antiemetic drug delivery: An alternative approach to oral and parenteral routes

Drug Development and Industrial Pharmacy

Volumn 36, Issue 7, 2010, Pages 806-813

  Gungor, Sevgi ^a   Okyar, Alper ^a   Erturk Toker, Sidika ^a   Baktir, Gul ^a   Ozsoy, Yildiz ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Chitosan; Microsphere; Nasal delivery; Ondansetron hydrochloride; Spray drying

Indexed keywords

CHITOSAN; GLUTARALDEHYDE; MICROSPHERE; NANOPARTICLE; ONDANSETRON;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; CROSS LINKING; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RELEASE; ENCAPSULATION; FEMALE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PARTICLE SIZE; RAT; SINGLE DRUG DOSE; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; ZETA POTENTIAL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIEMETICS; BIOLOGICAL AVAILABILITY; CHITOSAN; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; FEMALE; MALE; MICROSPHERES; ONDANSETRON; PARTICLE SIZE; RATS; RATS, WISTAR; TECHNOLOGY, PHARMACEUTICAL;

EID: 77953192026     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903517906     Document Type: Article

References (33)

1. Veyrat-Follet C, Farinotti R, Palmer JL. (1997). Physiology of chemotherapy-induced emesis and anti-emetic therapy. Predictive models for evaluation of new compounds. Drugs, 53:206-34.
2. Gregory RE, Ettinger DS. (1998). 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs, 55:173-89.
3. Scarantino CW, Ornitz RD, Hoffman LG. (1992). Radiation-induced emesis: Effects of ondansetron. Semin Oncol, 19:38-43.
4. Wilde MI, Markham A. (1996). Ondansetron: A review of its pharmacology and preliminary clinical findings in novel applications. Drugs, 52:773-94.
5. Roila F, Del Favero A. (1995). Ondansetron clinical pharmacokinetics. Clin Pharmacokinet, 29:95-109.
6. Fromm MF. (2002). The influence of MDR1 polymorphisms on P-glycoprotein expression and function on humans. Adv Drug Deliv Rev, 54:1295-310.
7. Hussain AA, Dakkuri A, Itoh S. (2000). Nasal absorption of ondansetron in rats: An alternative route of drug delivery. Cancer Chemother Pharmacol, 45:432-4.
8. Cho E, Gwak H, Chun I. (2008). Formulation and evaluation of ondansetron nasal delivery systems. Int J Pharm, 349:101-7.
9. Gungor S, Okyar A, Ertürk-Toker S, Baktir G, Ozsoy Y. (2009). Ondansetron-loaded biodegradable microspheres as a nasal sustained delivery system: In vitro/In vivo studies. Pharm Dev Technol (doi: 10.1080/ 10837450903148257).
10. Mygind N, Dahl R. (1998). Anatomy, physiology and function of the nasal cavities in health and disease. Adv Drug Deliv Rev, 29:3-12.
11. Ozsoy Y. (2008). Particulate carriers for nasal administration. In: Kumar MNVR, ed. Handbook of particulate drug delivery. CA: American Scientific Publisher, 143-64.
12. Chowdary KPR, Rao YS. (2004). Mucoadhesive microspheres for controlled drug delivery. Biol Pharm Bull, 27:1717-24.
13. Gavini E, Rassu G, Sanna V, Cossu M, Giunchedi P. (2005). Mucoadhesive microspheres for nasal administration of an antiemetic drug, metoclopramide: In-vitro/ex-vivo studies. J Pharm Pharmacol, 57:287-94.
14. Gavini E, Hegge AB, Rassu G, Sanna V, Testa C, Pirisino G, et al. (2006). Nasal administration of carbamazepine using chitosan microspheres: In vitro/in vivo studies. Int J Pharm, 307:9-15.
15. Lehr CM, Bouwstra JA, Schacht EH, Junginger HE. (1992). In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int J Pharm, 78:43-8.
16. Singla AK, Chawla M. (2001). Chitosan: Some pharmaceutical and biological aspects - an update. J Pharm Pharmacol, 53: 1047-67.
17. Soane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Illum L. (1999). Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm, 178:55-65.
18. Artursson P, Lindmark T, Davis SS, Illum L. (1994). Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res, 11:1358-61.
19. Sinha VR, Singla AK, Wadhawan S, Kaushik R, Kumria R, Bansal K, et al. (2004). Chitosan microspheres as a potential carrier for drugs. Int J Pharm, 274:1-33.
20. Hafner A, Filipović-Grcić J, Voinovich D, Jalsenjak I. (2007). Development and in vitro characterization of chitosan-based microspheres for nasal delivery of promethazine. Drug Dev Ind Pharm, 33:427-36.
21. Asane GS, Nirmal SA, Rasal KB, Naik AA, Mahadik MS, Rao YM. (2008). Polymers for mucoadhesive drug delivery system: A current status. Drug Dev Ind Pharm, 34:1246-66.
22. Hussain AA. (1998). Intranasal drug delivery. Adv Drug Deliv Rev, 29:39-49.
23. Rowland M, Tozer TN. (1995). Clinical pharmacokinetics: Concepts and applications. 3rd ed. Philadelphia: Lippincott Williams & Wilkins.
24. Giunchedi P, Juliano C, Gavini E, Cossu M, Sorrenti M. (2002). Formulation and in vivo evaluation of chlorhexidine buccal tablets prepared using drug-loaded chitosan microspheres. Eur J Pharm Biopharm, 53:233-9.
25. Martinac A, Filipović-Grcić J, Voinovich D, Perissutti B, Franceschinis E. (2005). Development and bioadhesive properties of chitosan-ethylcellulose microspheres for nasal delivery. Int J Pharm, 291:69-77.
26. Akbuǧa J, Durmaz G. (1994). Preparation and evaluation of crosslinked chitosan microspheres containing furosemide. Preparation and evaluation of cross-linked chitosan microspheres containing furosemide. Int J Pharm, 111:217-22.
27. Jameela SR, Jayakrishnan A. (1995). Glutaraldehyde cross-linked chitosan microspheres as a long acting biodegradable drug delivery vehicle: Studies on the in vitro release of mitoxantrone and in vivo degradation of microspheres in rat muscle. Biomaterials, 16:769-75.
28. He P, Davis SS, Illum L. (1998). In vitro evaluation of the mucoadhesive properties of chitosan microspheres. Int J Pharm, 166:75-88.
29. He P, Davis SS, Illum L. (1999). Chitosan microspheres prepared by spray drying. Int J Pharm, 187:53-65.
30. Ventura CA, Tommasini S, Crupi E, Giannone I, Cardile V, Musumeci T, et al. (2008). Chitosan microspheres for intrapul-monary administration of moxifloxacin: Interaction with biomembrane models and in vitro permeation studies. Eur J Pharm Biopharm, 68:235-44.
31. Donovan MD, Huang Y. (1998). Large molecule and particulate uptake in the nasal cavity: The effect of size on nasal absorption. Adv Drug Deliv Rev, 29:147-55.
32. Illum L, Fisher AN, Jabbal-Gill I, Davis SS. (2001). Bioadhesive starch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides. Int J Pharm, 222:109-19.
33. Alpar HO, Somavarapu S, Atuah KN, Bramwell VW. (2005). Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev, 57:411-30.